Valneva 将来の成長
Future 基準チェック /66
Valneva利益と収益がそれぞれ年間59.4%と20.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に61.1% 61.9%なると予測されています。
主要情報
59.4%
収益成長率
61.86%
EPS成長率
| Biotechs 収益成長 | 58.6% |
| 収益成長率 | 20.4% |
| 将来の株主資本利益率 | 61.08% |
| アナリストカバレッジ | Good |
| 最終更新日 | 01 Jun 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 13
VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment
Analysts have reduced their price target on Valneva from €10.00 to €7.50, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples as reflected in the latest fair value analysis. What's in the News Valneva revised its 2026 product sales guidance to a range of €135 million to €150 million, with total revenue guidance set at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets driven by geopolitical factors.
ナラティブの更新 • May 30
VLA: Weaker Travel Vaccine Demand Will Drive Cautious View On Shares
Analysts have slightly reduced their Valneva price target from €2.15 to €2.10, citing revised assumptions around revenue growth, profit margins and a higher implied future P/E multiple in their updated models. What's in the News Valneva adjusted its 2026 guidance, setting product sales in a range of €135 million to €150 million and total revenue guidance at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets linked to geopolitical factors (Corporate Guidance, Lowered).分析記事 • May 15
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...ナラティブの更新 • May 03
VLA: Lyme Vaccine Progress And Equity Raise Will Shape Balanced Outlook
Analysts have reduced their price target for Valneva from €3.25 to €2.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Valneva filed a follow on equity offering of €37.03 million, covering 15,893,817 ordinary shares at €2.33 per share with attached warrants, under Regulation S (Key Developments).ナラティブの更新 • Apr 18
VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.ナラティブの更新 • Apr 03
VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).
ナラティブの更新 • Mar 20
VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential
Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).ナラティブの更新 • Mar 06
VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment
Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.ナラティブの更新 • Feb 20
VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential
Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.ナラティブの更新 • Feb 05
VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential
Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).ナラティブの更新 • Jan 22
VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment
Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).ナラティブの更新 • Jan 07
VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential
Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).ナラティブの更新 • Dec 14
VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk
Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.分析記事 • Oct 01
Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Despite an already strong run, Valneva SE ( EPA:VLA ) shares have been powering on, with a gain of 29% in the last...分析記事 • Sep 10
Is Valneva (EPA:VLA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...ナラティブの更新 • Aug 24
Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets
Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.分析記事 • Jul 24
Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Valneva SE ( EPA:VLA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...新しいナラティブ • May 14
Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.分析記事 • Feb 20
Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Market forces rained on the parade of Valneva SE ( EPA:VLA ) shareholders today, when the analysts downgraded their...分析記事 • Feb 06
Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Valneva SE ( EPA:VLA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand. Not all...分析記事 • Nov 22
Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Valneva SE ( EPA:VLA ) share price has dived 25% in the last thirty days...分析記事 • Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest quarterly results and things are looking bullish. Results overall were...分析記事 • Sep 19
Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Valneva SE ( EPA:VLA ) shares have had a horrible month, losing 29% after a relatively good period beforehand. For any...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 251 | 39 | 8 | 82 | 8 |
| 12/31/2027 | 294 | 71 | 92 | 110 | 9 |
| 12/31/2026 | 152 | -66 | -62 | -62 | 9 |
| 3/31/2026 | 156 | -138 | -48 | -45 | N/A |
| 12/31/2025 | 175 | -115 | -57 | -53 | N/A |
| 9/30/2025 | 180 | -102 | -19 | -19 | N/A |
| 6/30/2025 | 196 | -67 | -27 | -12 | N/A |
| 3/31/2025 | 186 | -80 | -60 | -47 | N/A |
| 12/31/2024 | 170 | -12 | -84 | -67 | N/A |
| 9/30/2024 | 159 | -7 | -169 | -143 | N/A |
| 6/30/2024 | 156 | -32 | -215 | -204 | N/A |
| 3/31/2024 | 153 | -24 | -222 | -207 | N/A |
| 12/31/2023 | 154 | -101 | -217 | -203 | N/A |
| 9/30/2023 | 223 | -113 | -208 | -193 | N/A |
| 6/30/2023 | 426 | -7 | -231 | -211 | N/A |
| 3/31/2023 | 373 | -135 | -267 | -243 | N/A |
| 12/31/2022 | 361 | -143 | -275 | -245 | N/A |
| 9/30/2022 | 439 | 73 | -195 | -149 | N/A |
| 6/30/2022 | 304 | -159 | -177 | -108 | N/A |
| 3/31/2022 | 347 | -72 | -83 | 2 | N/A |
| 12/31/2021 | 348 | -73 | -16 | 77 | N/A |
| 9/30/2021 | 121 | -248 | 15 | 97 | N/A |
| 6/30/2021 | 110 | -125 | 51 | 109 | N/A |
| 3/31/2021 | 98 | -91 | 147 | 182 | N/A |
| 12/31/2020 | 110 | -64 | 118 | 138 | N/A |
| 9/30/2020 | 104 | -62 | 67 | 78 | N/A |
| 6/30/2020 | 120 | -25 | 97 | 105 | N/A |
| 3/31/2020 | 127 | -8 | -7 | 3 | N/A |
| 12/31/2019 | 126 | -2 | N/A | 6 | N/A |
| 9/30/2019 | 116 | 4 | N/A | 10 | N/A |
| 6/30/2019 | 109 | 1 | N/A | 16 | N/A |
| 3/31/2019 | 116 | 7 | N/A | 17 | N/A |
| 12/31/2018 | 113 | 3 | N/A | 16 | N/A |
| 9/30/2018 | 107 | -7 | N/A | 6 | N/A |
| 6/30/2018 | 110 | -7 | N/A | 10 | N/A |
| 3/31/2018 | 108 | -8 | N/A | 5 | N/A |
| 12/31/2017 | 105 | -11 | N/A | 13 | N/A |
| 9/30/2017 | 103 | -11 | N/A | 17 | N/A |
| 6/30/2017 | 100 | -14 | N/A | 19 | N/A |
| 3/31/2017 | 102 | -46 | N/A | 25 | N/A |
| 12/31/2016 | 98 | -49 | N/A | 7 | N/A |
| 9/30/2016 | 93 | -63 | N/A | 4 | N/A |
| 6/30/2016 | 96 | -61 | N/A | -5 | N/A |
| 3/31/2016 | 89 | -35 | N/A | -17 | N/A |
| 12/31/2015 | 83 | -21 | N/A | -20 | N/A |
| 9/30/2015 | 74 | -16 | N/A | -24 | N/A |
| 6/30/2015 | 65 | -13 | N/A | -19 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: VLAは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。
収益対市場: VLA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: VLA今後 3 年以内に収益を上げることが予想されます。
収益対市場: VLAの収益 ( 20.4% ) French市場 ( 5.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: VLAの収益 ( 20.4% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: VLAの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 61.1 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/18 23:06 |
| 終値 | 2026/06/18 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Valneva SE 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |